Key takeaway: Anlon Healthcare Limited's investor presentation for Q1 and FY 27 detailed the company's operations as a research-driven chemical manufacturer based in Rajkot, Gujarat. The presentation highlighted recent acquisitions, including a 56.67% stake in Bizotic Lifescience and a 67.48% stake in Apiqo Organics, aimed at enhancing capacity and regulatory readiness. Anlon reported a total installed manufacturing capacity of 1,400-1,600 MTPA and a diverse product portfolio with 65 commercialized products. The company emphasized its strategic transition from an API-focused manufacturer to an integrated pharmaceutical company, including entry into finished dosage formulations. Financial metrics showed significant revenue growth, with total income for Q1 FY27 reported at ₹87.62 crore, compared to ₹33.31 crore in Q1 FY26. Management set a goal of approximately 30% revenue CAGR over the next three years, supported by acquisitions and new product launches.

Key takeaway: Anlon Healthcare Limited reported strong financial growth for FY26, with total income increasing by 42.98% year-on-year to INR 172.22 crore. EBITDA rose by 47.55% to INR 47.77 crore, and profit after tax grew by 41.77% to INR 29.09 crore. The fourth quarter saw total income of INR 50.90 crore, slightly up from INR 48.97 crore in Q4 FY25, but profit before tax decreased to INR 14.44 crore from INR 15.49 crore. Management highlighted the importance of their strategic acquisitions, which enhanced capacity and regulatory readiness. They reported a healthy capacity utilization of approximately 62% and outlined plans to launch seven new APIs in FY27. Management set a goal of achieving INR 380 to 400 crore in revenue for FY27, with a long-term revenue CAGR of approximately 30%. They also indicated a focus on maintaining EBITDA margins between 25% and 30%.

Key takeaway: Anlon Healthcare Limited's investor presentation for Q4 and FY 2026 detailed the company's operations as a research-driven chemical manufacturer based in Rajkot, Gujarat. The presentation highlighted recent acquisitions, including a 67.48% stake in Apiqo Organics and a 56.67% stake in Bizotic Lifescience, aimed at enhancing capacity and regulatory readiness. Anlon reported a total installed manufacturing capacity of 1,400-1,600 MTPA and a workforce of 105 employees. The company has filed 21 Drug Master Files with global authorities and aims for a revenue CAGR of approximately 30% over the next three years. Financial metrics showed revenues increasing from INR 66.58 crore in FY24 to INR 171.97 crore in FY26, with a PAT of INR 29.09 crore for FY26. The presentation also outlined strategic initiatives for growth, including diversification into industrial chemicals and new product development.

Key takeaway: Anlon Healthcare Limited reported strong financial performance for Q3 FY 26, with total income reaching 35.78 crore, up from 9.38 crore in Q3 FY 25, driven by increased API and intermediate volumes. EBITDA was 12.54 crore, with margins at 35.06%, and PAT was 5.15 crore, a significant improvement from a loss in the previous year. For the nine months ended FY 26, total income rose to 121.32 crore from 71.49 crore in the same period last year. Management highlighted ongoing strategic initiatives, including the acquisition of Apiqo Organic to enhance capacity and backward integration, and plans for further acquisitions. They set a revenue goal of 170-180 crore for FY 26 and 370-380 crore for FY 27, emphasizing a focus on expanding their presence in regulated markets and launching new APIs. Management expressed confidence in achieving a 30% revenue CAGR over the next three years, supported by operational improvements and a robust order book.

Key takeaway: Anlon Healthcare Limited's investor presentation for Q3 and 9M of FY26 detailed the company's operations as a manufacturer of high-purity pharmaceutical intermediates and APIs, with a global presence in 15 countries. The presentation highlighted two significant acquisitions: a 56.67% stake in Bizotic Lifescience Pvt. Ltd. and a 67.48% stake in Apiqo Organics Pvt. Ltd., aimed at enhancing capacity and regulatory readiness. Management reported a projected total capacity of 1,400–1,600 MTPA by FY26, supported by a strong R&D pipeline and 21 global DMF filings. Financial metrics showed a substantial increase in revenues, with total income rising from INR 71.49 crore in 9M FY25 to INR 121.32 crore in 9M FY26. The company set a goal of approximately 30% revenue CAGR over the next three years, driven by acquisitions and new product launches. The presentation concluded with a focus on strategic growth initiatives and market opportunities in various sectors.